Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This trial adopts a randomized, double-blind, positive drug-controlled, dose-escalated phase
Ib clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and
preliminary effectiveness of recombinant human serum albumin in patients with liver cirrhosis
and ascites
subjects (both male and female) were screened and enrolled to the three dose levels of 10g,
20 g,and 30 g according to the principle of dose escalation, and 8 out of 12 subjects in each
dose group One patient received the test drug, and 4 received a positive drug.